Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIBGet Rating) in a research note issued on Wednesday. The brokerage set a “buy” rating on the stock.

NASDAQ:TRIB opened at $1.13 on Wednesday. Trinity Biotech has a 52 week low of $0.86 and a 52 week high of $3.98. The firm has a market cap of $23.62 million, a price-to-earnings ratio of 12.56 and a beta of 1.55. The firm’s 50-day simple moving average is $1.06 and its 200 day simple moving average is $1.44.

Trinity Biotech (NASDAQ:TRIBGet Rating) last released its quarterly earnings results on Monday, April 11th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.13). Trinity Biotech had a negative return on equity of 27,745.46% and a net margin of 0.94%.

A number of hedge funds have recently added to or reduced their stakes in the business. Hunter Associates Investment Management LLC increased its holdings in Trinity Biotech by 5.5% in the 1st quarter. Hunter Associates Investment Management LLC now owns 2,412,116 shares of the company’s stock valued at $2,557,000 after buying an additional 125,966 shares during the period. LPL Financial LLC increased its holdings in Trinity Biotech by 20.1% in the 4th quarter. LPL Financial LLC now owns 106,973 shares of the company’s stock valued at $153,000 after buying an additional 17,900 shares during the period. Whitefort Capital Management LP bought a new position in Trinity Biotech in the 4th quarter valued at about $50,000. Envestnet Asset Management Inc. bought a new position in Trinity Biotech in the 4th quarter valued at about $159,000. Finally, Wealthsource Partners LLC bought a new position in Trinity Biotech in the 3rd quarter valued at about $65,000. 27.83% of the stock is currently owned by hedge funds and other institutional investors.

About Trinity Biotech (Get Rating)

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Featured Articles

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.